Randomized, Double-Blind, Pharmacokinetic (PK) and Glucodynamic (GD) Crossover Study of Continuous Subcutaneous Insulin Infusion (CSII) of Rapid Acting Insulin Analogs With and Without Recombinant Human Hyaluronidase (rHuPH20).
Phase of Trial: Phase I
Latest Information Update: 13 Aug 2014
At a glance
- Drugs Insulin glulisine (Primary) ; Insulin aspart
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Halozyme Therapeutics
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 28 Jun 2011 Final results presented in a late-breaking session at the 71st Scientific Sessions of the American Diabetes Association (ADA).
- 24 Jun 2011 Status changed from recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History